Lv1
28 积分 2022-12-09 加入
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
1个月前
已完结
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors
3个月前
已完结
Antibody–oligonucleotide conjugates enter the clinic
6个月前
已完结
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
7个月前
已完结
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
7个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
9个月前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
9个月前
已完结
Development Strategy for Innovation System of Radiopharmaceuticals in China
10个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1年前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
1年前
已完结
皖公网安备34019202002308
